伊米达衍生物对细胞增殖和细胞亡在骨髓性白血病的作用
Bazla Binte Nadeem1, Aysha Bibi1, Mudassir Khan1
1Department of Biomedicine, Atta-ur-Rahman School of Applied Biosciences, National University of Sciences and Technology, Islamabad, Pakistan.
BMC cancer
|September 28, 2024
概括
新型伊米达衍生物在治疗急性肌肉细胞白血病 (APL) 和慢性肌肉细胞白血病 (CML) 中表现有前途,通过抑制癌细胞生长和诱导亡. 这些化合物向关键路径,为耐药白血病提供潜在的新治疗策略.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 药用化学 医学化学
背景情况:
- 急性肌肉细胞白血病 (APL) 和慢性肌肉细胞白血病 (CML) 具有特定的转位和对当前疗法的耐药性.
- 白血病干细胞 (LSC) 有助于APL和CML的复发和抵抗.
- 目前APL和CML治疗的局限性需要开发新的治疗药物.
研究的目的:
- 评估四种新型伊米达衍生物的抗白血病作用.
- 评估这些衍生物对APL (NB4) 和CML (K562) 细胞系的影响.
- 调查它们抗白血病活性的潜在分子机制.
主要方法:
- 用药理和生化分析来评估细胞增殖.
- 评估了诱导亡的方法.
- 实时聚合酶链反应 (RT-PCR) 用于分析基因表达,包括AXL-受体氨酸激酶 (AXL-RTK) 和Wnt/β-catenin通路的标.
主要成果:
- 四种伊米达衍生物都抑制了NB4 (APL) 细胞的增殖;L-7也影响了K562 (CML) 细胞.
- 抗增殖效应与亡诱导有关.
- 伊米达衍生物降低了AXL-RTK和Wnt/β-catenin通路向基因 (c-Myc,Axin2,EYA3) 的下调.
- 用L-7和标准药物 (ATRA或Imatinib) 进行的组合治疗显示出添加效应和进一步的基因下调.
结论:
- 新的伊米达衍生物有效地降低了APL和CML细胞的增殖.
- 这些化合物诱导了亡,并降低了关键的分子标,如AXL-RTK和Wnt/β-catenin通路基因.
- 这些发现表明,伊米达衍生物有可能成为新的抗白血病药物,特别是在组合疗法中.
相关概念视频
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
The Intrinsic Apoptotic Pathway
6.4K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
6.4K
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
233
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
Phenothiazines, such as prochlorperazine...
233
Abnormal Proliferation
4.5K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
Inhibition of Cdk Activity
4.7K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K


